The Pharmacodynamic Impact of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, on Circulating Levels of Inflammatory Biomarkers in Patients with Psoriatic Arthritis: Substudy Results from a Phase III, Randomized, Placebo-Controlled Trial (PALACE 1)

Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor

(2014) Arthur Kavanaugh et al.   ANNALS OF THE RHEUMATIC DISEASES

Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity

(2014) P.H. Schafer et al.   CELLULAR SIGNALLING

Cellular sources of IL-17 in psoriasis: a paradigm shift?

(2014) Romy R. M. C. Keijsers et al.   EXPERIMENTAL DERMATOLOGY

Hemostatic and Fibrinolytic Changes Are Related to Inflammatory Conditions in Patients with Psoriatic Arthritis -- Effect of Different Treatments

(2014) M. N. D. Di Minno et al.   JOURNAL OF RHEUMATOLOGY

Keratinocyte Overexpression of IL-17C Promotes Psoriasiform Skin Inflammation

(2013) A. Johnston et al.   JOURNAL OF IMMUNOLOGY

Soluble Biomarkers Associated with Response to Treatment with Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis

(2013) V. Chandran et al.   JOURNAL OF RHEUMATOLOGY

Markers of inflammation and bone remodelling associated with improvement in clinical response measures in psoriatic arthritis patients treated with golimumab

(2012) Carrie L Wagner et al.   ANNALS OF THE RHEUMATIC DISEASES

Apremilast mechanism of action and application to psoriasis and psoriatic arthritis

(2012) Peter Schafer   BIOCHEMICAL PHARMACOLOGY

The role of inflammatory markers in assessing disease severity and response to treatment in patients with psoriasis treated with etanercept

(2011) A. Kanelleas et al.   CLINICAL AND EXPERIMENTAL DERMATOLOGY

Evaluation of various endothelial biomarkers in ankylosing spondylitis

(2011) Ali Taylan et al.   CLINICAL RHEUMATOLOGY

Circulating levels of interleukin-6, vascular endothelial growth factor, YKL-40, matrix metalloproteinase-3, and total aggrecan in spondyloarthritis patients during 3 years of treatment with TNFα inhibitors

(2010) Susanne Juhl Pedersen et al.   CLINICAL RHEUMATOLOGY

Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis

(2010) Fiona E McCann et al.   ARTHRITIS RESEARCH & THERAPY

Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases

(2010) Georg Schett et al.   Therapeutic Advances in Musculoskeletal Disease

Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis

(2009) PH Schafer et al.   BRITISH JOURNAL OF PHARMACOLOGY

Wide-spectrum profile of inflammatory mediators in the plasma and scales of patients with psoriatic disease

(2009) Irina Deeva et al.   CYTOKINE

An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast

(2008) A. B. Gottlieb et al.   CURRENT MEDICAL RESEARCH AND OPINION